Deutsche Bank and Truist Go Bullish on Ascentage Pharma
Ascentage Pharma gets Buy ratings; its cancer drugs show strong results, fast growth in China, and high future upside potential.
/ 2 items
Ascentage Pharma gets Buy ratings; its cancer drugs show strong results, fast growth in China, and high future upside potential.
Ascentage Pharma receives FDA clearance for APG-3288, an innovative BTK protein degrader designed to treat resistant blood cancers through a novel degradation approach.